SCHEMBL4185604

SCHEMBL4185604

COC(=O)c1ccccc1Sc1ccc(CCl)cc1N

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.47
KDM4E B2RXH2 6/20 0.47
TDP1 Q9NUW8 1/20 0.47
HSD17B10 Q99714 5/20 0.47
CFTR P13569 1/20 0.47
SLC6A2 P23975 7/20 0.46
SLC6A4 P31645 7/20 0.46
POLB P06746 1/20 0.46
LMNA P02545 3/20 0.45
GAA P10253 2/20 0.45
MAPT P10636 6/20 0.45
HPGD P15428 4/20 0.45
ALOX15 P16050 2/20 0.45
TSHR P16473 1/20 0.45
PKLR P30613 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
SLC6A3 Q01959 1/20 0.43
PKM P14618 1/20 0.42
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4185602 0.89 ALDH1A1 (0.42) ALDH1A1KDM4ETDP1HSD17B10CFTR
SCHEMBL4173713 0.84 KDM4E (0.66) ALDH1A1KDM4ETDP1SLC6A2SLC6A4
SCHEMBL3409694 0.83 ABL1 (0.60) ALDH1A1KDM4ETDP1HSD17B10CFTR
Hydrochloric Acid SCHEMBL15227699 0.82 ABL1 (0.58) ALDH1A1KDM4ETDP1HSD17B10CFTR
SCHEMBL9860403 0.82 ALDH1A1 (0.54) ALDH1A1KDM4ETDP1HSD17B10CFTR
SCHEMBL17080270 0.82 ALDH1A1 (0.62) ALDH1A1KDM4ETDP1HSD17B10CFTR
SCHEMBL3838973 0.81 SLC6A4 (0.56) ALDH1A1KDM4ETDP1HSD17B10SLC6A2
SCHEMBL1340573 0.81 ALDH1A1 (0.66) ALDH1A1KDM4ETDP1HSD17B10CFTR
SCHEMBL21939814 0.80 ALDH1A1 (0.75) ALDH1A1KDM4ETDP1HSD17B10CFTR
SCHEMBL4440485 0.78 HSD17B10 (0.64) ALDH1A1KDM4ETDP1HSD17B10CFTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149442-A1 Atypical antipsychotic agents having low affinity for the D2 receptor KAPUR SHITIJ 2009-06-11 US disclosed
EP-1406881-B8 11-PIPERAZINYLDIBENZO(B,F)(1,4)OXAZEPINES AND THIAZEPINES AS ATYPICAL ANTIPSYCHOTIC AGENTS HAVING LOW AFFINITY FOR THE D2 RECEPTOR CAMH (CA) 2006-10-25 EP disclosed
EP-1406881-B1 11-PIPERAZINYLDIBENZO(B,F)(1,4)OXAZEPINES AND THIAZEPINES AS ATYPICAL ANTIPSYCHOTIC AGENTS HAVING LOW AFFINITY FOR THE D2 RECEPTOR NEUROMOLECULAR INC (CA) 2006-09-13 EP disclosed
US-20060166965-A1 Atypical antipsychotic agents having low affinity for the D2 receptor KAPUR SHITIJ 2006-07-27 US disclosed
EP-1593676-A1 8-Chloro-11-(4-(2'-hydroxyethyl)piperazin-1-yl)-dibenzo[b,f][1,4]oxazepine of atypical anti-psychotic activity and having a low affinity for the dopamine D2 receptor Neuromolecular, Inc. (CA) 2005-11-09 EP disclosed
US-20050222121-A1 Atypical antipsychotic agents having low affinity for the D2 receptor KAPUR SHITIJ 2005-10-06 US disclosed
US-6890919-B2 Atypical antipsychotic agents having low affinity for the D2 receptor KAPUR SHITIJ (CA) 2005-05-10 US disclosed
EP-1406881-A1 11-PIPERAZINYLDIBENZO(B,F)(1,4)OXAZEPINES AND THIAZEPINES AS ATYPICAL ANTIPSYCHOTIC AGENTS HAVING LOW AFFINITY FOR THE D2 RECEPTOR Neuromolecular, Inc. (CA) 2004-04-14 EP disclosed
US-20030135042-A1 Atypical antipsychotic agents having low affinity for the D2 Receptor NEUROMOLECULAR, INC. (CA) 2003-07-17 US disclosed
WO-2003000670-A1 A11-PIPERAZINYLDIBENZO (B, F) (1, 4) OXAZEPINES AND THIAZEPINES AS ATYPICAL ANTIPSYCHOTIC AGENTS HAVING LOW AFFINITY FOR THE D2 RECEPTOR NEUROMOLECULAR, INC. (CA) 2003-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149442-A1 Atypical antipsychotic agents having low affinity for the D2 receptor DRD2, OPRD1, GRIN2A ALDH1A1 1345/4885KDM4E 4024/4885TDP1 4461/4885
US-20050222121-A1 Atypical antipsychotic agents having low affinity for the D2 receptor DRD2, OPRD1, GRIN2A ALDH1A1 1345/4885KDM4E 4024/4885TDP1 4461/4885
US-20060166965-A1 Atypical antipsychotic agents having low affinity for the D2 receptor DRD2, OPRD1, GRIN2A ALDH1A1 1345/4885KDM4E 4024/4885TDP1 4461/4885
US-20030135042-A1 Atypical antipsychotic agents having low affinity for the D2 Receptor OPRD1, HTR1A, DRD2 ALDH1A1 894/4885KDM4E 4181/4885TDP1 4180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.